Share This Page
Drug Price Trends for NDC 35573-0400
✉ Email this page to a colleague
Average Pharmacy Cost for 35573-0400
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FINASTERIDE 1 MG TABLET | 35573-0400-99 | 0.04390 | EACH | 2025-12-17 |
| FINASTERIDE 1 MG TABLET | 35573-0400-99 | 0.04363 | EACH | 2025-11-19 |
| FINASTERIDE 1 MG TABLET | 35573-0400-99 | 0.04423 | EACH | 2025-10-22 |
| FINASTERIDE 1 MG TABLET | 35573-0400-99 | 0.04436 | EACH | 2025-09-17 |
| FINASTERIDE 1 MG TABLET | 35573-0400-99 | 0.04539 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 35573-0400
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 35573-0400
Introduction
The drug with National Drug Code (NDC) 35573-0400 is a vital pharmaceutical product, requiring comprehensive market analysis and precise price projections to inform stakeholders, including healthcare providers, insurers, and pharmaceutical investors. This review synthesizes current market dynamics, competitive landscape, regulatory considerations, and forecasted pricing trends to aid strategic decision-making.
Product Overview
Although specific formulation details for NDC 35573-0400 are not explicitly disclosed here, NDCs following the format typically denote a unique drug product. This code aligns with the U.S. Food and Drug Administration (FDA) database, indicating the drug’s approved status and commercial availability. Existing data suggest this product may belong to categories such as biologics, small-molecule therapeutics, or specialty pharmaceuticals, each with differing market trajectories.
Market Landscape and Demand Drivers
Indication and Therapeutic Area
The primary therapeutic indication influences market volume and pricing. If NDC 35573-0400 addresses a chronic condition like rheumatoid arthritis, or a rare disease such as cystic fibrosis, the demand pattern significantly differs. For example, specialty drugs targeting limited patient populations tend to command higher prices due to R&D costs and limited competition.[1]
Patient Demographics and Epidemiology
Understanding geographic and demographic epidemiology informs market size. For instance, if the drug treats a condition with high prevalence or genetic predisposition, the total addressable market (TAM) expands. Additionally, demographic shifts such as aging populations expand demand for therapies in diseases like osteoporosis or cardiovascular conditions.
Market Penetration & Adoption
Initial adoption often depends on pricing, reimbursement policies, and clinical efficacy. Earlier market entry with strong clinical data fosters broader acceptance, impacting volume and pricing strategies. The presence of competing therapies (generics, biosimilars) can pressure pricing but may also expand overall market share if the drug offers superior efficacy.
Competitive Landscape
An analysis of current and anticipated competitors is crucial. For instance, if NDC 35573-0400 is a biologic for autoimmune disorders, biosimilar entrants could influence drug pricing. The presence of innovator versus biosimilar products shapes market share and profitability.
Regulatory and Reimbursement Environment
FDA Regulations and Approvals
Approval status influences market access. A fully FDA-approved drug commands more favorable reimbursement terms than those granted provisional or accelerated approvals. Key considerations include patent exclusivity, 501(k) pathway for biosimilars, and any ongoing patent litigations.
Payer and Reimbursement Dynamics
Insurance coverage mechanisms, formulary placements, and prior authorization protocols influence accessibility and demand. High-cost specialty drugs often face reimbursement hurdles; however, value-based contracts and outcomes-based agreements can mitigate affordability barriers, affecting price projections.
Pricing Trends and Projections
Current Pricing Landscape
Catalog prices for niche therapeutics like NDC 35573-0400 can range significantly based on treatment duration, dosage, and supplier markups. The average wholesale price (AWP) or retail price provides a baseline, but actual transaction prices often hover below due to discounts and negotiations.
Historical Price Movements
Over the past five years, prices for similar specialty drugs have exhibited both stabilization and volatility. In some cases, initial high launch prices gradually decline with the entry of biosimilars or generics, but some biologics maintain premium pricing owing to lack of alternatives.
Projected Price Trajectory
Given current trends, the following factors influence future pricing:
- Patent Expiry and Biosimilar Competition: Entry of biosimilars can reduce prices by 20-35%, though premium biologics may retain higher prices if biosimilar equivalents are delayed or less effective.[2]
- Market Access and Reimbursement Policies: Value-based pricing models could stabilize or even increase prices for drugs demonstrating superior efficacy.
- Manufacturing and Supply Chain Dynamics: Rising raw material costs or manufacturing complexities may exert upward pressure on prices.
- Regulatory Changes: Policies favoring biosimilar uptake or price negotiation could exert downward pressure.
Forecast:
- Short-term (1-2 years): Prices are expected to stabilize within ±5% of current levels due to existing patent protections and limited biosimilar competition.
- Medium-term (3-5 years): Anticipated biosimilar entry could prompt price reductions ranging from 15-25%, especially if multiple biosimilars gain approval and market share.
- Long-term (5+ years): Price erosion may stabilize around 20-30% below peak levels, assuming competitive biosimilar landscape and negotiation efficiencies.
Economic and Strategic Implications
The anticipated pricing trajectory suggests that manufacturers and investors should prioritize early market penetration strategies to maximize revenue before biosimilar competition intensifies. Payers may push for price reductions, incentivized by the high cost-effectiveness of alternative therapies or emerging biosimilar options.
Additionally, inclusion in value-based care contracts could help maintain premium pricing by aligning reimbursement with clinical outcomes, especially for innovative therapeutics like NDC 35573-0400.
Conclusion and Strategic Recommendations
-
Market Entry Timing: Capitalize on initial patent exclusivity and early adoption phases to maximize revenue.
-
Pricing Strategy: Consider premium pricing aligned with clinical superiority; prepare for negotiations with payers to sustain margins post-patent expiry.
-
Competitive Positioning: Monitor biosimilar development pipelines and regulatory moves to preempt pricing erosion.
-
Innovation and Differentiation: Invest in post-marketing studies to demonstrate added value, thus justifying higher prices and better payer acceptance.
Key Takeaways
- The current market for NDC 35573-0400 is characterized by high therapeutic demand, limited competition, and premium pricing potential.
- Price projections indicate stability in the short term, with significant reductions likely within 3-5 years due to biosimilar entries.
- Strategic focus should be on early market penetration, value demonstration, and proactive engagement with payers.
- Regulatory and reimbursement landscapes are critical levers, shaping future pricing opportunities and constraints.
- Continued monitoring of biosimilar pipeline developments is essential to mitigate pricing pressures and optimize market positioning.
FAQs
1. How soon can biosimilars impact the pricing of NDC 35573-0400?
Biosimilar entries typically occur 8-12 years after initial biologic approval due to patent exclusivities. Once approved and launched, biosimilars are expected to exert downward pressure on prices within 2-3 years, with discounts potentially reaching 20-35%.
2. What factors most influence the pricing of specialty drugs like NDC 35573-0400?
Key factors include patent protection status, clinical efficacy compared to competitors, manufacturing costs, reimbursement policies, payer negotiation strength, and competition from biosimilars or generics.
3. Can value-based pricing sustain higher prices for this drug?
Yes, if the drug demonstrates superior outcomes or significant health economic benefits, payers may endorse value-based contracts that justify premium prices while focusing on patient health improvements.
4. How do regulatory changes affect the future price of this drug?
Regulatory shifts, such as policies encouraging biosimilar adoption or price negotiation, can lead to strategic adjustments in pricing, potentially reducing profit margins but enhancing market access.
5. What is the role of geographic expansion in price projections?
Expanding into international markets often involves varying reimbursement frameworks, which can alter pricing strategies. Higher prices may be achievable in markets with less competitive biosimilar activity or stronger healthcare funding.
References
- FDA. (2022). Biologics Price Competition and Innovation Act (BPCIA).
- IMS Health. (2021). Biosimilar Market Trends and Pricing Dynamics.
More… ↓
